CENP-A stands for centromere proteins A.
Centromere antibodies can be directed against a number of centromere proteins (CENP), including CENP-A, -B, and -C, though CENP-B is thought to be the main target.
These antibodies are found in 20% to 40% of patients with SSc and are associated with the lcSSc subtype.
Furthermore, centromere antibodies are included in the 2013 ACR-EULAR classification criteria. However, these antibodies can occur in other connective tissue diseases, including:
- systemic lupus erythematosus (SLE),
- primary biliary cholangitis,
- rheumatoid arthritis,
- and Sjögren syndrome.
Presence of centromere antibodies is considered predictive of SSc development in patients with Raynaud phenomenon (a problem that causes decreased blood flow to the fingers. In some cases, it also causes less blood flow to the ears, toes, nipples, knees, or nose. This happens due to spasms of blood vessels in those areas. The spasms happen in response to cold, stress, or emotional upset.)
The antibodies are associated with lower risk of cardiac and renal involvement but higher risk of PAH (= pulmonary arterial hypertension). For patients without PAH, centromere antibodies are associated with a better prognosis overall than are other autoantibodies.
Systemic Sclerosis Classification Criteria:
|
Classify as having systemic sclerosis if the sum of points for criteria below is ≥9. |
|
|
Criterion |
Points |
|
Skin thickened on fingers of both hands, extending proximal to the metacarpophalangeal joints |
9 |
|
Skin on fingers thickened (only count highest score) Puffy fingers Sclerodactylya |
2 4 |
|
Lesions on fingertips (only count highest score) Ulcers on tip of digits Pitting scars on fingertips |
2 3 |
|
Telangiectasia |
2 |
|
Abnormal nailfold capillaries |
2 |
|
Pulmonary arterial hypertension and/or interstitial lung disease (max score is 2) Pulmonary arterial hypertension Interstitial lung disease |
2 2 |
|
Raynaud phenomenon |
3 |
|
Presence of 1 or more of the following: Centromere antibody Scl-70 antibody RNA polymerase III antibody |
3 |
Clinical Characteristics Associated With Autoantibodies Used in the Diagnosis and Classification of Systemic Sclerosisa:
|
Antibody |
Prevalence in SSc, % |
Presence in other autoimmune diseases |
SSc type most likely |
Clinical associations |
Relative SSc prognosis |
|
ANA |
85-95 |
Common |
Does not help differentiate type |
Most common in rheumatic diseases |
Varies |
|
Centromere A or B |
20-40 b |
Uncommon |
lcSSc |
PAH, calcinosis, digital ischemia, intestinal involvement |
Better |
|
Ku |
1.5-5 |
Common |
Overlap syndromes or lcSSc |
Muscle and joint involvement |
Unclear |
|
PM/Scl-75 or PM/Scl-100 |
2-11 |
Common |
SSc-myositis overlap syndrome or lcSSc |
Muscle and joint involvement, calcinosis; GI and lung involvement for those with PM/Scl-75 |
Better |
|
RNA Polymerase III |
7-41 |
Rare |
dcSSc |
Renal crisis, progressive skin thickening, GAVE, malignancy |
Poorer |
|
Scl-70 |
9.4-71 b |
Rare |
dcSSc |
Severe pulmonary fibrosis, cardiac involvement, renal crisis, digital ulcers |
Poorer |
|
Th/To |
2-5 |
Rare |
lcSSc |
Pulmonary involvement |
Poorer |
|
U1-snRNP |
2-14 |
Common (90% in patients with MCTD) |
lcSSc |
PAH, arthritis, esophageal dysfunction |
Better |
|
U3-RNP (Fibrillarin) |
4-10 b |
Rare |
dcSSc |
Multiorgan involvement, PAH |
Poorer |
| ANA, antinuclear antibodies; dcSSc, diffuse cutaneous systemic sclerosis; GAVE, gastric antral vascular ectasia; GI, gastrointestinal; lcSSc, limited cutaneous systemic sclerosis; MCTD, mixed connective tissue disease; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis. | |
| a | Data presented in this table have been compiled from the cited references. It is important to note that autoantibody frequency in SSc as well as other autoimmune diseases varies with sex, ethnicity, and population studied. |
| b | In the United States, prevalence has been shown to vary across ethnicities. |
References:
van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747. doi:10.1002/art.38098
Stochmal A, Czuwara J, Trojanowska M, et al. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40-51. doi:10.1007/s12016-018-8718-8
Kayser C, Fritzler MJ. Autoantibodies in systemic sclerosis: unanswered questions. Front Immunol. 2015;6:167. doi:10.3389/fimmu.2015.00167
Hamaguchi Y, Takehara K. Anti-nuclear autoantibodies in systemic sclerosis: news and perspectives. J Scleroderma Relat Disord. 2018;3(3):201-213. doi:10.1177/2397198318783930
Mahler M, Meroni PL, Bossuyt X, et al. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res. 2014;2014:315179. doi:10.1155/2014/315179
Cavazzana I, Fredi M, Taraborelli M, et al. A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Clin Exp Rheumatol. 2013;31(2 suppl 76):118-121.
D'Aoust J, Hudson M, Tatibouet S, et al. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol. 2014;66(6):1608-1615. doi:10.1002/art.38428
Wodkowski M, Hudson M, Proudman S, et al. Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. Autoimmunity. 2015;48(8):542-551. doi:10.3109/08916934.2015.1077231
Shah AA, Hummers LK, Casciola-Rosen L, et al. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma. Arthritis Rheumatol. 2015;67(4):1053-1061. doi:10.1002/art.39022
Sobanski V, Dauchet L, Lefèvre G, et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol. 2014;66(2):407-417. doi:10.1002/art.38219
Pokeerbux MR, Giovannelli J, Dauchet L, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther. 2019;21(1):86. doi:10.1186/s13075-019-1867-1
Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12(3):340-354. doi:10.1016/j.autrev.2012.05.011
Krzyszczak ME, Li Y, Ross SJ, et al. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol. 2011;30(10):1333-1339. doi:10.1007/s10067-011-1751-0
Nandiwada SL, Peterson LK, Mayes MD, et al. Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis. J Rheumatol. 2016;43(10):1816-1824. doi:10.3899/jrheum.160106
Federico Perosa, Marcella Prete, Giuseppe Di Lernia, Carmela Ostuni, Elvira Favoino, Gabriele Valentini, Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin, Autoimmunity Reviews, Volume 15, Issue 1, 2016, Pages 102-109, ISSN 1568-9972, https://doi.org/10.1016/j.autrev.2015.10.001.
What does it mean if your CENP-A result is too high?
Systemic sclerosis (SSc) is systemic, autoimmune, connective tissue disorder characterized by vascular abnormalities, collagen deposition (fibrosis), and the production of autoantibodies to nuclear proteins. About 20%–40% of patients have antibodies to centromere protein (CENP)-A or -B.
All Your Lab Results.
One Simple Dashboard.
Import, Track, and Share Your Lab Results Easily
Import, Track, and Share Your Lab Results
Import lab results from multiple providers, track changes over time, customize your reference ranges, and get clear explanations for each result. Everything is stored securely, exportable in one organized file, and shareable with your doctor—or anyone you choose.
Cancel or upgrade anytime
Laboratories
Bring All Your Lab Results Together — In One Place
We accept reports from any lab, so you can easily collect and organize all your health information in one secure spot.
Pricing Table
Gather Your Lab History — and Finally Make Sense of It
Finally, Your Lab Results Organized and Clear
Personal plans
$79/ year
Advanced Plan
Access your lab reports, explanations, and tracking tools.
- Import lab results from any provider
- Track all results with visual tools
- Customize your reference ranges
- Export your full lab history anytime
- Share results securely with anyone
- Receive 5 reports entered for you
- Cancel or upgrade anytime
$250/ once
Unlimited Account
Pay once, access everything—no monthly fees, no limits.
- Import lab results from any provider
- Track all results with visual tools
- Customize your reference ranges
- Export your full lab history anytime
- Share results securely with anyone
- Receive 10 reports entered for you
- No subscriptions. No extra fees.
$45/ month
Pro Monthly
Designed for professionals managing their clients' lab reports
- Import lab results from any provider
- Track lab results for multiple clients
- Customize reference ranges per client
- Export lab histories and reports
- Begin with first report entered by us
- Cancel or upgrade anytime
About membership
What's included in a Healthmatters membership
Import Lab Results from Any Source
See Your Health Timeline
Understand What Your Results Mean
Visualize Your Results
Data Entry Service for Your Reports
Securely Share With Anyone You Trust
Let Your Lab Results Tell the Full Story
Once your results are in one place, see the bigger picture — track trends over time, compare data side by side, export your full history, and share securely with anyone you trust.
Bring all your results together to compare, track progress, export your history, and share securely.
What Healthmatters Members Are Saying
Frequently asked questions
Healthmatters is a personal health dashboard that helps you organize and understand your lab results. It collects and displays your medical test data from any lab in one secure, easy-to-use platform.
- Individuals who want to track and understand their health over time.
- Health professionals, such as doctors, nutritionists, and wellness coaches, need to manage and interpret lab data for their clients.
With a Healthmatters account, you can:
- Upload lab reports from any lab
- View your data in interactive graphs, tables, and timelines
- Track trends and monitor changes over time
- Customize your reference ranges
- Export and share your full lab history
- Access your results anytime, from any device
Professionals can also analyze client data more efficiently and save time managing lab reports.
Healthmatters.io personal account provides in-depth research on 10000+ biomarkers, including information and suggestions for test panels such as, but not limited to:
- The GI Effects® Comprehensive Stool Profile,
- GI-MAP,
- The NutrEval FMV®,
- The ION Profile,
- Amino Acids Profile,
- Dried Urine Test for Comprehensive Hormones (DUTCH),
- Organic Acids Test,
- Organix Comprehensive Profile,
- Toxic Metals,
- Complete Blood Count (CBC),
- Metabolic panel,
- Thyroid panel,
- Lipid Panel,
- Urinalysis,
- And many, many more.
You can combine all test reports inside your Healthmatters account and keep them in one place. It gives you an excellent overview of all your health data. Once you retest, you can add new results and compare them.
If you are still determining whether Healthmatters support your lab results, the rule is that if you can test it, you can upload it to Healthmatters.
We implement proven measures to keep your data safe.
At HealthMatters, we're committed to maintaining the security and confidentiality of your personal information. We've put industry-leading security standards in place to help protect against the loss, misuse, or alteration of the information under our control. We use procedural, physical, and electronic security methods designed to prevent unauthorized people from getting access to this information. Our internal code of conduct adds additional privacy protection. All data is backed up multiple times a day and encrypted using SSL certificates. See our Privacy Policy for more details.